An oral pill to be taken once a night has shown promising effects in alleviating apnea events in patients with OSA and could present an alternative for patients unable to cope with CPAP. In an important phase 3 study, the drug under investigation, AD109 was shown to reduce apnea and hypopnea occurrences by approximately 44 percent when compared to placebo, while also increasing sleep oxygen saturation. Results are based on the SynAIRgy trial, in which 646 adults with mild, moderate or severe OSAS were recruited from 69 sites in the US and Canada.
All patients had refused CPAP or been unable to tolerate it. At 26 weeks, those receiving AD109 had a 44.1 percent model-estimated reduction in baseline apnea-hypopnea index and 17.
6 percent for placebo. Over 40 percent of active patient had lowered their disease severity classification, and nearly 18 percent achieved complete disease control (less than five events per hour). AD109 (a fixed-dose tablet of aroxybutynin and atomoxetine taken at bedtime)AD109 is a new proposal which has been designed to be taken at bedtime combining two commercially available agents: aroxybutynin and atomoxetine.
Unlike CPAP, it doesn’t open up the airway with pressurized air, but it targets the neuromuscular control mechanisms responsible for sleep-related upper airway collapse by relieving one of the condition’s underlying causative factors. The lead researcher, Patrick John Strollo, a sleep medicine physician at the University of Pittsburgh Medical Center, said, ‘there is encouraging evidence here that pursuit of neuromuscular dysfunction as a target in therapy can yield defined clinical gains.’ Oxygenation improved also, with decreases in oxygen desaturation index and hypoxic burden.
The benefits seemed to be independent of severity levels or body mass, so the approach may be for lots of patients. Adverse events were generally mild, dry mouth, nausea and some bouts of insomnia were reported. More discontinuation were due to adverse events in AD109 category group than placebo.
This aspect will be reviewed later when this therapy is currently under review again by regulatory agency. The Food and Drug Administration (FDA) has accepted a new drug application for AD109 with a decision estimate in 2027. For the several million who do not or cannot use CPAP there is hope in the form of a pill.
The current standard of care involves uncomfortable, inconvenient, and embarrassing nightly use of a pressurized-mask connected to a device. An oral choice would ease the path for many in adhering to therapy and the health consequences thereof including heart disease, hypoxic brain injury, and somnolence. The trial results do not mean that the pill is going to replace machines on everyone’s bedside.
Absolute reductions in events provide for many patients residual disease, and long term data are just beginning to emerge. But, the capacity for dramatic early demonstration of great benefit of a once-nightly tablet is an achievement. With advancing research into separate biologic factors of sleep apnea, targeted oral approaches such as AD109 can be added into a personalized treatment plan.
